Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study.
Fiche publication
Date publication
juillet 2022
Journal
Gynecologic oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr KURTZ Jean-Emmanuel, Dr SPAETH Dominique, Dr KAMINSKY Marie-Christine, Dr BENGRINE-LEFEVRE Leila
Tous les auteurs :
Joly F, Fabbro M, Berton D, Lequesne J, Anota A, Puszkiel A, Floquet A, Vegas H, Bourgeois H, Bengrine Lefevre L, You B, Pommeret F, Lortholary A, Spaeth D, Hardy-Bessard AC, Abdeddaim C, Kaminsky-Forrett MC, Tod M, Kurtz JE, Del Piano F, Meunier J, Raban N, Alexandre J, Mouret-Reynier MA, Ray-Coquard I, Provansal Gross M, Brachet PE
Lien Pubmed
Résumé
Anti-angiogenic rechallenge with bevacizumab plus chemotherapy is effective in recurrent ovarian cancer (rOC); however, data are limited on tyrosine kinase inhibitors after progression on maintenance bevacizumab.
Mots clés
Anti-angiogenic, Bevacizumab, Pazopanib, Rechallenge, Recurrent ovarian cancer, Tyrosine kinase inhibitor
Référence
Gynecol Oncol. 2022 07 25;: